PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
11.73%
Revenue growth above 1.5x MRVL's 4.29%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
14.88%
Gross profit growth above 1.5x MRVL's 3.82%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
23.57%
EBIT growth above 1.5x MRVL's 8.09%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
23.57%
Operating income growth 1.25-1.5x MRVL's 15.99%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
38.27%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
60.00%
Positive EPS growth while MRVL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
60.00%
Positive diluted EPS growth while MRVL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-10.96%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-10.96%
Reduced diluted shares while MRVL is at 1.17%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
22.52%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
121.15%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
219.05%
Positive FCF growth while MRVL is negative. John Neff would see a strong competitive edge in net cash generation.
57.39%
Similar 10Y revenue/share CAGR to MRVL's 56.20%. Walter Schloss might see both firms benefiting from the same long-term demand.
30.73%
5Y revenue/share CAGR under 50% of MRVL's 109.65%. Michael Burry would suspect a significant competitive gap or product weakness.
32.70%
3Y revenue/share CAGR 1.25-1.5x MRVL's 25.49%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.94%
3Y OCF/share CAGR 1.25-1.5x MRVL's 63.72%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
747.03%
Net income/share CAGR 1.25-1.5x MRVL's 653.69%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
18.05%
Below 50% of MRVL's 220.76%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
921.88%
3Y net income/share CAGR above 1.5x MRVL's 202.86%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.89%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
77.23%
10Y dividend/share CAGR above 1.5x MRVL's 0.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
64.10%
Stable or rising mid-term dividends while MRVL is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
0.36%
Our short-term dividend growth is positive while MRVL cut theirs. John Neff views it as a comparative advantage in shareholder returns.
3.67%
AR growth is negative/stable vs. MRVL's 11.24%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
3.00%
Inventory growth well above MRVL's 4.05%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
2.34%
Positive asset growth while MRVL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
18.75%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
-1.71%
We’re deleveraging while MRVL stands at 3.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
11.28%
We expand SG&A while MRVL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.